TLDR Dupilumab effectively treats severe skin issues in a rare genetic disorder.
The study highlights the effective use of dupilumab, a monoclonal antibody, in treating severe atopic dermatitis in patients with X-linked recessive ectodysplasin A mutations, which cause hypohidrotic ectodermal dysplasia. This genetic disorder is marked by a lack of sweat glands and severe skin issues. The treatment led to significant improvement in the patient's condition, suggesting that dupilumab could be a promising option for managing skin symptoms in this rare disorder.
15 citations
,
December 2020 in “International journal of molecular sciences” Epidermal stem cells create and maintain skin structures like hair and nails through specific signaling pathways and vary by location and function.
12 citations
,
March 2013 Minoxidil cream can safely treat hair loss in kids with ectodermal dysplasia.
May 2023 in “Journal of Clinical Medicine” New understanding and treatments for hair loss are improving, but more research is needed.
1 citations
,
March 2024 in “BioDrugs” Biologics for severe asthma have known side effects, but some new risks need more study.
49 citations
,
December 2018 in “Journal of Investigational Allergology and Clinical Immunology” Dupilumab may cause hair loss in some patients with severe atopic dermatitis.
28 citations
,
June 2021 in “Frontiers in immunology” A protein called lfTSLP is important in causing allergic and other skin diseases and could be a target for treatment.
1 citations
,
May 2023 in “Prospects in Pharmaceutical Sciences” New cytokine-targeted therapies show promise for treating alopecia areata.
